Clinical study of recombinant human granulocyte colony stimulating factor (rhG-CSF) on leukopenia induced by chemotherapy in cancer patients
Shi, Y.K.; Zhou, J.C.; Feng, F.Y.
Zhonghua Zhong Liu Za Zhi 16(3): 207-210
1994
ISSN/ISBN: 0253-3766 PMID: 7525173 Document Number: 425494
The clinical usefulness of Recombinant Human Granulocyte Colony Stimulating Factor (rhG-CSF, Filgrastim, GRAN) was evaluated in patients with leukopenia and neutropenia following chemotherapy for non-Hodgkin's lymphoma, lung cancer and breast cancer. During chemotherapy when patients' leukocyte count (WBC) fell below 4.0 times 10-9/L. rhG-CSF(GRAN) at a dose of 75-mu-g/body cntdot day was given subcutaneously 48 hours after the termination of chemotherapy. The results indicated that rhG-CSF(GRAN) could elevate nadirs of WBC and significantly shortened leukopenic period with WBC below 4.0 times 10-9/L and expedited the recovery of WBC to levels above 4.0 times 10-9/L. The response of granulocytes to rhG-CSF(GRAN) was similar to that of WBC. rhG-CSF (GRAN)'s side effects were mild.